Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kazia Therapeutics Ltd ADR
(NQ:
KZIA
)
0.3569
+0.0069 (+1.97%)
Streaming Delayed Price
Updated: 10:36 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kazia Therapeutics Ltd ADR
Kazia Therapeutics CEO talks $4.5 million capital raise
January 18, 2023
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner speaks with Proactive after confirming a two-tranche capital raising initiative to raise A$4.5 million through placements to...
Via
TheNewswire.com
Kazia Therapeutics (KZIA): Collaboration May Expand Utility to Combo Therapies
December 19, 2022
Via
ACCESSWIRE
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
November 02, 2022
Via
ACCESSWIRE
Kazia Therapeutics (KZIA): Doubling Down on Clinical Development
September 07, 2022
Via
ACCESSWIRE
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US
July 20, 2022
KAZIA RECOGNISES GBM AWARENESS DAY 2022 AS IT EXPANDS CLININCAL TRIAL ACTIVITY IN EUROPE AND US Sydney, 20 July 2022 – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug...
Via
iCrowdNewswire
Kazia Therapeutics (KZIA): Deep Dive Into Childhood Brain Cancer
May 26, 2022
LONDON, UK / ACCESSWIRE / May 26, 2022 / In light of the positive newsflow from Kazia's efforts in addressing adult brain cancer, management is leveraging its niche expertise and experience to address...
From
Edison Investment Research Limited
Via
AccessWire
Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
March 30, 2022
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential...
From
Edison Investment Research Limited
Via
AccessWire
Kazia TherapeuticsTrust (KZIA): Multiple Paxalisib Data Points Expected in Q4
October 14, 2021
LONDON, UK / ACCESSWIRE / October 14, 2021 / Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in newly...
From
Edison Investment Research Limited
Via
AccessWire
Kazia Therapeutics (KZIA): New asset to target tumor lymphangiogenesis
April 20, 2021
LONDON, UK / ACCESSWIRE / April 20, 2021 / Kazia announced that it is expanding its pipeline to include EVT801, a novel small molecule inhibitor of VEGFR3. The drug is being licensed from Evotec for...
From
Edison Investment Research Limited
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.